Dismantling relapsed/refractory mantle cell lymphoma

2024-9-1

Editorial Board

2024-9-1

Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future

2024-9-1

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies

2024-9-1

Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH

2024-9-1

Corrigendum to “Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?”[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226]

2024-9-1

Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?

2024-8-1

Autologous stem cell transplantation in AL amyloidosis: Muddy waters

2024-8-1

Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy

2024-8-1

Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation

2024-8-1

Ven the dose matters: Venetoclax dosing in the frontline treatment of AML

2024-8-1

Longitudinal clinical manifestations of Fanconi anemia: A systematized review

2024-8-1

Editorial Board

2024-7-1

Current challenges in conditioning regimens for MDS transplantation

2024-7-1

Breaking down frailty: Assessing vulnerability in acute myeloid leukemia

2024-7-1

Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria

2024-7-1

Cancer cytogenetics in a genomics world: Wedding the old with the new

2024-7-1

Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk

2024-6-7

Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature

2024-6-6

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide

2024-6-3

Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment

2024-6-1

The acute pain crisis in sickle cell disease: What can be done to improve outcomes?

2024-5-1

Revolutionising healing: Gene Editing's breakthrough against sickle cell disease

2024-5-1

When anticoagulation management in atrial fibrillation becomes difficult: Focus on chronic kidney disease, coagulation disorders, and cancer

2024-5-1

Update: The molecular spectrum of virus-associated high-grade B-cell non-Hodgkin lymphomas

2024-5-1

Editorial Board

2024-5-1

Disparity in hematological malignancies: From patients to health care professionals

2024-5-1

De-novo immune-mediated thrombotic thrombocytopenic purpura following surgical and non-surgical procedures: A systematic review

2024-4-9

Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis

2024-4-1

Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia

2024-4-1

Chronic myeloid leukaemia: Biology and therapy

2024-3-27

BCL-2 inhibition in haematological malignancies: Clinical application and complications

2024-3-21

Chromosomal defects in multiple myeloma

2024-3-1

Optimizing high dose melphalan

2024-3-1

Platelet factor 4(PF4) and its multiple roles in diseases

2024-3-1

From microscope to micropixels: A rapid review of artificial intelligence for the peripheral blood film

2024-3-1

Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances

2024-3-1

Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies

2024-3-1

Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management

2024-3-1

Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]

2024-3-1

Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A

2024-3-1

Richter's transformation: Transforming the clinical landscape

2024-3-1

Editorial Board

2024-3-1

Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape

2024-3-1

Iron deficiency anemia among women: An issue of health equity

2024-3-1

Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia

2024-3-1

Contemporary tools for evaluation of hemostasis in neonates. Where are we and where are we headed?

2024-3-1

Down syndrome and leukemia: An insight into the disease biology and current treatment options

2024-3-1

Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era

2024-3-1

Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia

2024-2-1